9.11 ABSTRACT University of Minnesota Cancer Center (UMCC) trial review and monitoring oversight is based on NCI/NIH guidelines to ensure the safety of participants and the validity of clinical trial data. Review of protocols for scientific merit and study progress is conducted by the Cancer Protocol Review Committees (CPRC). The responsibilities of the CPRCs are distinct from those of the Data and Safety Monitoring Council (DSMC) which has oversight of monitoring activities and data validity. The CPRCs review all University of Minnesota clinical cancer protocols including investigator initiated and industry-sponsored trials. The two CPRC committees are the Intervention Trials (CPRC-TI) Committee chaired by Robert Kratzke, MD, Chair and the Non-Therapeutic Intervention Trials (CPRC-NTI) Committee chaired by Julie Ross, PhD, Chair. The CPRCs may approve or disapprove a study for lack of scientific merit or progress. The DSMG chaired by Gregory Vercellotti, MD functions independently from the IRB and oversees data, safety and monitoring of ongoing clinical cancer trials. The DSMC primarily evaluates investigatOMnitiated trials. The DSMC makes recommendations to the Clinical Research Leadership Committee (CRL) to suspend or close a trial if the risk to subjects is thought to be excessive or to outweigh potential benefits. The DSMC Chair has the authority to temporarily suspend a trial without CRL approval in situations requiring immediate action. AUcommittee chairs are appointed by the Clinical Research Leadership Committee. The Cancer Center Clinical Trials office administratively supports the three committees.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Abbott, Kenneth L; Nyre, Erik T; Abrahante, Juan et al. (2015) The Candidate Cancer Gene Database: a database of cancer driver genes from forward genetic screens in mice. Nucleic Acids Res 43:D844-8
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Daniel, A R; Gaviglio, A L; Knutson, T P et al. (2015) Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34:506-15
Upadhyaya, Pramod; Hecht, Stephen S (2015) Quantitative analysis of 3'-hydroxynorcotinine in human urine. Nicotine Tob Res 17:524-9
Patel, Yesha M; Stram, Daniel O; Wilkens, Lynne R et al. (2015) The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev 24:119-27
Chen, Liddy M; Ibrahim, Joseph G; Chu, Haitao (2014) Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. J Biopharm Stat 24:817-33
Takahashi, Yutaka; Hui, Susanta K (2014) Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy. Radiat Oncol 9:34
Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600
Gorden, Brandi H; Kim, Jong-Hyuk; Sarver, Aaron L et al. (2014) Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. Am J Pathol 184:985-95
Landman, Sean R; Hwang, Tae Hyun; Silverstein, Kevin A T et al. (2014) SHEAR: sample heterogeneity estimation and assembly by reference. BMC Genomics 15:84

Showing the most recent 10 out of 319 publications